NA
PHIO icon

Nordwand Advisors’s Phio Pharmaceuticals PHIO Stock Holding History

Nordwand Advisors’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-500
Closed -$1.73K – 133
2024
Q3 		$1.73K Buy
+500
New +$1.79K ﹤0.01% 126

Other funds holding PHIO

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Nordwand Advisors's PHIO Position: Q4 2024 in Review

Nordwand Advisors sold out of Phio Pharmaceuticals (PHIO) in Q4 2024, closing a stake of 500 shares — an estimated $1.73K sold.

Nordwand Advisors first reported a position in PHIO in Q3 2024 and held it in 1 quarter. The position peaked at $1.73K in Q3 2024. 11 funds tracked by Wall St. Rank hold PHIO as of Q4 2024.

  • Nordwand Advisors reported no remaining Phio Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Nordwand Advisors sold 500 Phio Pharmaceuticals shares in Q4 2024, an estimated $1.73K.
  • Nordwand Advisors first reported a position in Phio Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Nordwand Advisors's Phio Pharmaceuticals position peaked at $1.73K in Q3 2024.
  • 11 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q4 2024.

Based on Nordwand Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.